Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multicenter, Open-Label, Single-Arm, Multicohort Phase II Clinical Trial of Trastuzumab Deruxtecan(DS-8201a) in Human Epidermal Growth Factor Receptor 2 HER2+ Advanced Breast Cancer With Brain Metastases and/or Leptomeningeal Carcinomatosis

NCT04420598 is registered in ClinicalTrials.gov with MedSIR as lead sponsor.

NCT NCT04420598
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04420598 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multicenter, Open-Label, Single-Arm, Multicohort Phase II Clinical Trial of Trastuzumab Deruxtecan(DS-8201a) in Human Epidermal Growth Factor Receptor 2 HER2+ Advanced Breast Cancer With Brain Metastases and/or Leptomeningeal Carcinomatosis
Lead sponsor
MedSIR
Phase
Phase 2
Overall status
Completed
Start date
May 25, 2020
Completion date
April 4, 2023
Enrollment
41 (actual)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

advanced breast cancer, brain metastases, her2-positive breast cancer, leptomeningeal metastasis